Ahead of IgG4-RD Awareness Day on April 4th, we recognize the impact of IgG4-RD, a rare, chronic condition that can affect multiple organ systems and lead to progressive, irreversible damage. As we continue to help raise awareness, we remain committed to advancing new treatment options for those affected by IgG4-RD. Learn more: https://lnkd.in/gsyYFn8W #ZenasBio #AutoimmuneDisease #IgG4RD #IgG4RDAwarenessDay
Zenas BioPharma
Biotechnology Research
Waltham, MA 12,487 followers
Enabling patients with autoimmune diseases to reimagine life
About us
Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.
- Website
-
https://zenasbio.com/
External link for Zenas BioPharma
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, MA
- Type
- Public Company
- Specialties
- Autoimmune Diseases and Immunology
Locations
-
Primary
Get directions
1000 Winter St
Suite 1200
Waltham, MA 02451, US
-
Get directions
1515 West Nanjing Road
Level 7, Tower 2, Jing'an Kerry Center
Jing'an District, Shanghai 200041, CN
Employees at Zenas BioPharma
Updates
-
Recently, our team united in wearing orange to demonstrate our support for the millions of people affected by Multiple Sclerosis (MS). Together, we seek to raise awareness and reaffirm our commitment to the MS community as we continue to advance our clinical trials. Learn more: https://lnkd.in/gsyYFn8W #ZenasBio #MSAwarenessMonth #MultipleSclerosis
-
-
Today we announced our fourth quarter and full year 2025 financial results and corporate updates. Last year was a transformative year for Zenas and we look forward to continuing this momentum in 2026. Learn more: https://lnkd.in/eyG-wr37 #ZenasBio #AutoimmuneDisease #IgG4RD #MultipleSclerosis #SystemicLupusErythematosus
-
-
This March, Zenas is proud to support Autoimmune Disease Awareness Month. We are committed to advancing several clinical programs for the treatment of autoimmune diseases, including IgG4-RD, MS and SLE. Learn more: https://lnkd.in/gsyYFn8W #ZenasBio #AutoimmuneAwarenessMonth #AutoimmuneDisease #IgG4RD #MultipleSclerosis #SystemicLupusErythematosus
-
-
Today we’re recognizing Rare Disease Day and the IgG4-RD community! This is a chronic fibro-inflammatory disease with limited treatment options. We are proud to advance a potential new therapy for patients with IgG4-RD and are committed to understand the perspectives of people living with this disease, their care partners and doctors. Learn more about IgG4-RD here: https://lnkd.in/gsyYFn8W. #ZenasBio #RareDiseaseDay #AutoimmuneDisease #IgG4RD
-
-
We are pleased to announce positive results from the INDIGO Phase 3 Immunoglobulin G4-Related Disease (IgG4-RD) registrational trial, demonstrating our investigational treatment met the primary endpoint and all key secondary endpoints with high statistical significance. INDIGO is the largest clinical trial ever conducted in patients with IgG4-RD to date, reflecting significant dedication and important participation of patients and healthcare professionals. We intend to file for regulatory approval in the U.S. and Europe this year as we look to advance a potentially new treatment option for IgG4-RD patients. Join the Zenas management team for a conference call and webcast today at 8:00 a.m. ET. Register here: https://lnkd.in/eVfxuG5X Read the press release here: https://lnkd.in/e4ZXYshE #IgG4RD #AutoimmuneDisease #Biotech #ZenasBio
-
We are pleased to share exciting news from our partner InnoCare Pharma that our BTK inhibitor met its primary and secondary endpoints in a Phase 2b study sponsored by InnoCare in Greater China and Southeast Asia for Systemic Lupus Erythematosus (SLE). This is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE. Read more: https://lnkd.in/euNzfaJY #ZenasBio #AutoimmuneDisease #SystemicLupusErythematosus
-
We’re excited to welcome Heinrich Schlieker, Ph.D., as Zenas’ new Chief Technical Officer. Dr. Schlieker brings decades of global experience in pharmaceutical development, quality, manufacturing, and supply chain management. #ZenasBio #autoimmune #immunology #biotech
-
-
We’re pleased to share our third quarter 2025 financial results and corporate updates that reflect exceptional momentum across our programs for multiple autoimmune diseases. Learn more: https://lnkd.in/ekRMFX8P #ZenasBio #AutoimmuneDisease #IgG4RD #MultipleSclerosis #SystemicLupusErythematosus
-
-
We look forward to presenting at the Jefferies Global Healthcare Conference in London and the 8th Annual Evercore Healthcare Conference. Get the details here to hear our recent achievements and upcoming milestones: https://lnkd.in/ewkphwwJ #ZenasBio #autoimmune #biotech
-